Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Malignant Ascites 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Ovarian High Grade Serous Adenocarcinoma 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paracentesis 2irinotecan sucrosofate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Malignant Ascites × Paracentesis × 1 year × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

NCT06266091 2025-07-20

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 2 Completed
115 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡